f Post-Approval Studies (PAS) Database
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


Extended F/U-Barricaid ACD Premarket Cohort

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Inadequate
Application Number /
Requirement Number
P160050 / PAS001
Date Original Protocol Accepted 05/07/2019
Date Current Protocol Accepted 05/12/2020
Study Name Extended F/U-Barricaid ACD Premarket Cohort
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Concurrent Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives The purpose of this post-approval clinical study is to examine the long-term survivorship of the Barricaid® ACD when used in conjunction with limited
discectomy. This study is also intended to monitor the natural history of endplate lesions due to interactions with the device, potential interactions with the development of osteoporosis, lesion growth and lesion stability. The study is also intended to investigate potential underlying mechanisms that may contribute to any additional growth through retrieval analysis and histological analysis of periprosthetic tissue.
Extended Follow-up From a 2-Year RCT
Study Population Extended follow-up of RCT Subjects – investigational (Barricaid + Discectomy) vs control (Discectomy Alone)
Sample Size This study is not powered to demonstrate statistical conclusions, but rather the sample size is based on the subjects from the original 2-year study who agree to participate in longer-term follow-up.
Key Study Endpoints Secondary Surgical Intervention (SSI), SAEs, AEs, Device Failures, Radiographic Observations, Symptomatic Reherniations, All Reherniations
VAS, ODI will all be collected.

S005 - For Germany, Austria, Switzerland: CT for control subjects only when they experience a potentially related AE.
Follow-up Visits and Length of Follow-up 10 years, with potentially additional 3 year increments.

Extended F/U-Barricaid ACD Premarket Cohort Reporting Schedule

Reporting Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
6 month report 08/09/2019 09/18/2019 Overdue/Received
1 year report 02/08/2020 02/10/2020 Overdue/Received
18 month report 08/08/2020 08/06/2020 On Time
2 year report 02/07/2021 02/08/2021 Overdue/Received
3 year report 03/22/2022 03/22/2022 On Time
4 year report 02/07/2023    
5 year report 02/07/2024    
6 year report 02/06/2025    

Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources